Abstract
Osseous metastases and osteoporotic fractures are a serious problem in patients with prostate cancer. As androgen-deprivation therapy is being used earlier in the course of the disease, the risk of osteoporosis and insufficiency fractures is increasing. In this review, the contribution of androgen-deprivation therapy to osteoporosis and bone metastases will be discussed. The role of bisphosphonates in treating osteoporosis and bone metastases will also be reviewed. The review will conclude with a discussion of the toxicities associated with bisphosphonate use.